Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Amaran Biotech, Nippon Fine Chemical Sign MOU | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Amaran Biotech, Nippon Fine Chemical Sign MOU

Amaran Biotech will utilize its aseptic filling line and CDMO services to support Nippon Fine Chemical’s production of nanoparticle-based drugs.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

Amaran Biotechnology Inc., a subsidiary of OBI Pharma specializing in Contract Development and Manufacturing Organization (CDMO) services for next-generation pharmaceuticals, has signed a Memorandum of Understanding (MOU) with Nippon Fine Chemical Co., Ltd., and its Taiwan subsidiary, Zillion Fine Chemicals International Co., Ltd. The three parties aim to deepen collaboration in the field of nanoparticle-based drug CDMO manufacturing while expanding their presence in Taiwan, Japan, and international CDMO markets.

Through this partnership, Amaran Biotech will utilize its aseptic filling line and CDMO services to support Nippon Fine Chemical’s production of nanoparticle-based drugs, including liposomes and lipid nanoparticles (LNPs).

The services provided will include sterile filtration, aseptic filling, packaging, storage, and quality management. The collaboration also extends to Zillion Fine Chemicals’ CDMO operations in Taiwan, with the three parties working together to complement each other’s strengths and upgrade the technology and services of the CDMO markets in Taiwan, Japan, and beyond.

Ryan Lo, Vice President of Corporate Strategy, Business Development & Regulatory Affairs, Amaran Biotech, said, “Amaran’s industry-leading aseptic filling line and extensive experience in pharmaceutical production have earned Nippon Fine Chemical’s trust. This collaboration not only provides a more comprehensive solution for nanoparticle-based drug CDMO but also aims to create synergistic business opportunities that multiply the value of our efforts.”

Masaki Matsumoto, Senior General Manager of Nippon Fine Chemical, added: “The nanoparticle-based drug market holds tremendous growth potential. We believe this partnership will inject significant momentum into our CDMO business development in Japan, Taiwan, and the global market.”

Read about CDMO industry trends in 2025.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics